The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
An Open-label, Single-ascending dose, Phase I Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects